Correlation between copy number variation genes (focal events) and selected clinical features
Pancreatic Adenocarcinoma (Primary solid tumor)
23 September 2013  |  analyses__2013_09_23
Maintainer Information
Citation Information
Maintained by TCGA GDAC Team (Broad Institute/MD Anderson Cancer Center/Harvard Medical School)
Cite as Broad Institute TCGA Genome Data Analysis Center (2013): Correlation between copy number variation genes (focal events) and selected clinical features. Broad Institute of MIT and Harvard. doi:10.7908/C1RJ4GTG
Overview
Introduction

This pipeline computes the correlation between significant copy number variation (cnv focal) genes and selected clinical features.

Summary

Testing the association between copy number variation 44 focal events and 12 clinical features across 52 patients, no significant finding detected with Q value < 0.25.

  • No focal cnvs related to clinical features.

Results
Overview of the results

Table 1.  Get Full Table Overview of the association between significant copy number variation of 44 focal events and 12 clinical features. Shown in the table are P values (Q values). Thresholded by Q value < 0.25, no significant finding detected.

Clinical
Features
Time
to
Death
AGE NEOPLASM
DISEASESTAGE
PATHOLOGY
T
STAGE
PATHOLOGY
N
STAGE
PATHOLOGY
M
STAGE
GENDER HISTOLOGICAL
TYPE
NUMBERPACKYEARSSMOKED YEAROFTOBACCOSMOKINGONSET COMPLETENESS
OF
RESECTION
NUMBER
OF
LYMPH
NODES
nCNV (%) nWild-Type logrank test t-test Chi-square test Fisher's exact test Fisher's exact test Fisher's exact test Fisher's exact test Fisher's exact test t-test t-test Fisher's exact test t-test
AMP PEAK 1(1P34 2) MUTATION ANALYSIS 3 (6%) 49 0.159
(1.00)
0.947
(1.00)
1
(1.00)
1
(1.00)
0.193
(1.00)
0.59
(1.00)
0.271
(1.00)
0.0604
(1.00)
0.0112
(1.00)
AMP PEAK 2(1P12) MUTATION ANALYSIS 6 (12%) 46 0.574
(1.00)
0.909
(1.00)
0.568
(1.00)
1
(1.00)
0.612
(1.00)
0.284
(1.00)
0.674
(1.00)
1
(1.00)
0.52
(1.00)
0.241
(1.00)
AMP PEAK 3(7Q22 1) MUTATION ANALYSIS 13 (25%) 39 0.456
(1.00)
0.799
(1.00)
0.712
(1.00)
1
(1.00)
1
(1.00)
0.249
(1.00)
0.541
(1.00)
1
(1.00)
0.0604
(1.00)
0.619
(1.00)
AMP PEAK 4(8Q24 21) MUTATION ANALYSIS 19 (37%) 33 0.09
(1.00)
0.971
(1.00)
0.733
(1.00)
0.641
(1.00)
1
(1.00)
0.341
(1.00)
0.568
(1.00)
1
(1.00)
0.0344
(1.00)
0.51
(1.00)
0.385
(1.00)
0.241
(1.00)
AMP PEAK 5(9P13 3) MUTATION ANALYSIS 5 (10%) 47 0.0756
(1.00)
0.847
(1.00)
0.105
(1.00)
1
(1.00)
0.325
(1.00)
0.16
(1.00)
0.652
(1.00)
1
(1.00)
0.706
(1.00)
0.845
(1.00)
AMP PEAK 6(11P11 2) MUTATION ANALYSIS 4 (8%) 48 0.967
(1.00)
0.327
(1.00)
0.93
(1.00)
1
(1.00)
1
(1.00)
0.247
(1.00)
1
(1.00)
1
(1.00)
0.614
(1.00)
0.456
(1.00)
AMP PEAK 7(12P13 33) MUTATION ANALYSIS 7 (13%) 45 0.259
(1.00)
0.842
(1.00)
0.502
(1.00)
0.53
(1.00)
1
(1.00)
1
(1.00)
0.0396
(1.00)
0.48
(1.00)
0.267
(1.00)
0.67
(1.00)
AMP PEAK 8(12P11 21) MUTATION ANALYSIS 10 (19%) 42 0.253
(1.00)
0.218
(1.00)
0.428
(1.00)
1
(1.00)
1
(1.00)
0.361
(1.00)
0.0313
(1.00)
0.336
(1.00)
0.0234
(1.00)
0.741
(1.00)
AMP PEAK 9(12Q15) MUTATION ANALYSIS 6 (12%) 46 0.249
(1.00)
0.306
(1.00)
0.777
(1.00)
1
(1.00)
0.316
(1.00)
0.527
(1.00)
0.0836
(1.00)
0.0993
(1.00)
0.0461
(1.00)
0.465
(1.00)
AMP PEAK 10(17P11 2) MUTATION ANALYSIS 3 (6%) 49 0.0626
(1.00)
0.947
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
0.358
(1.00)
AMP PEAK 11(17Q21 33) MUTATION ANALYSIS 7 (13%) 45 0.483
(1.00)
0.231
(1.00)
0.657
(1.00)
1
(1.00)
0.656
(1.00)
0.574
(1.00)
0.69
(1.00)
1
(1.00)
1
(1.00)
0.658
(1.00)
AMP PEAK 12(18Q11 2) MUTATION ANALYSIS 14 (27%) 38 0.489
(1.00)
0.848
(1.00)
0.169
(1.00)
0.307
(1.00)
0.475
(1.00)
0.00325
(1.00)
1
(1.00)
1
(1.00)
0.461
(1.00)
0.415
(1.00)
0.0298
(1.00)
0.682
(1.00)
AMP PEAK 13(19Q13 13) MUTATION ANALYSIS 10 (19%) 42 0.912
(1.00)
0.982
(1.00)
0.738
(1.00)
0.569
(1.00)
1
(1.00)
0.828
(1.00)
0.157
(1.00)
0.655
(1.00)
0.711
(1.00)
0.382
(1.00)
1
(1.00)
0.816
(1.00)
AMP PEAK 14(20Q13 2) MUTATION ANALYSIS 13 (25%) 39 0.204
(1.00)
0.551
(1.00)
0.353
(1.00)
1
(1.00)
0.253
(1.00)
0.859
(1.00)
0.106
(1.00)
0.419
(1.00)
0.349
(1.00)
0.0825
(1.00)
AMP PEAK 15(XP22 11) MUTATION ANALYSIS 4 (8%) 48 0.899
(1.00)
0.426
(1.00)
0.902
(1.00)
1
(1.00)
0.562
(1.00)
1
(1.00)
0.0393
(1.00)
0.347
(1.00)
0.688
(1.00)
0.731
(1.00)
AMP PEAK 16(XQ27 1) MUTATION ANALYSIS 6 (12%) 46 0.94
(1.00)
0.905
(1.00)
0.472
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
0.397
(1.00)
0.416
(1.00)
0.149
(1.00)
0.911
(1.00)
DEL PEAK 1(1P36 22) MUTATION ANALYSIS 9 (17%) 43 0.196
(1.00)
0.0547
(1.00)
0.496
(1.00)
1
(1.00)
0.666
(1.00)
0.26
(1.00)
0.0637
(1.00)
0.638
(1.00)
0.282
(1.00)
0.155
(1.00)
0.333
(1.00)
0.173
(1.00)
DEL PEAK 2(1P36 11) MUTATION ANALYSIS 12 (23%) 40 0.21
(1.00)
0.275
(1.00)
0.703
(1.00)
1
(1.00)
0.709
(1.00)
0.184
(1.00)
0.0449
(1.00)
1
(1.00)
0.282
(1.00)
0.155
(1.00)
0.604
(1.00)
0.435
(1.00)
DEL PEAK 3(1P21 2) MUTATION ANALYSIS 9 (17%) 43 0.451
(1.00)
0.518
(1.00)
0.496
(1.00)
1
(1.00)
0.666
(1.00)
0.26
(1.00)
0.0637
(1.00)
0.638
(1.00)
0.282
(1.00)
0.155
(1.00)
0.146
(1.00)
0.258
(1.00)
DEL PEAK 4(5Q14 2) MUTATION ANALYSIS 9 (17%) 43 0.735
(1.00)
0.588
(1.00)
0.842
(1.00)
0.573
(1.00)
0.666
(1.00)
1
(1.00)
0.716
(1.00)
0.638
(1.00)
0.379
(1.00)
0.523
(1.00)
DEL PEAK 5(5Q15) MUTATION ANALYSIS 10 (19%) 42 0.735
(1.00)
0.376
(1.00)
0.789
(1.00)
0.569
(1.00)
0.42
(1.00)
1
(1.00)
0.483
(1.00)
1
(1.00)
0.333
(1.00)
0.505
(1.00)
DEL PEAK 6(6P25 2) MUTATION ANALYSIS 19 (37%) 33 0.0984
(1.00)
0.497
(1.00)
0.687
(1.00)
0.641
(1.00)
0.739
(1.00)
0.0425
(1.00)
0.253
(1.00)
0.749
(1.00)
0.953
(1.00)
0.704
(1.00)
0.887
(1.00)
0.608
(1.00)
DEL PEAK 7(6P22 3) MUTATION ANALYSIS 19 (37%) 33 0.372
(1.00)
0.566
(1.00)
0.687
(1.00)
0.641
(1.00)
0.739
(1.00)
0.167
(1.00)
0.0856
(1.00)
0.749
(1.00)
0.852
(1.00)
0.704
(1.00)
1
(1.00)
0.67
(1.00)
DEL PEAK 8(6Q22 33) MUTATION ANALYSIS 24 (46%) 28 0.177
(1.00)
0.843
(1.00)
0.53
(1.00)
0.358
(1.00)
1
(1.00)
0.0435
(1.00)
0.781
(1.00)
1
(1.00)
0.537
(1.00)
0.789
(1.00)
0.779
(1.00)
0.541
(1.00)
DEL PEAK 9(7Q36 1) MUTATION ANALYSIS 5 (10%) 47 0.734
(1.00)
0.771
(1.00)
0.408
(1.00)
0.41
(1.00)
1
(1.00)
1
(1.00)
0.652
(1.00)
1
(1.00)
1
(1.00)
0.881
(1.00)
DEL PEAK 10(8P21 3) MUTATION ANALYSIS 15 (29%) 37 0.212
(1.00)
0.241
(1.00)
0.362
(1.00)
1
(1.00)
0.47
(1.00)
0.479
(1.00)
0.234
(1.00)
0.5
(1.00)
0.282
(1.00)
0.0138
(1.00)
0.457
(1.00)
DEL PEAK 11(8Q12 1) MUTATION ANALYSIS 4 (8%) 48 0.567
(1.00)
0.352
(1.00)
0.302
(1.00)
1
(1.00)
1
(1.00)
0.122
(1.00)
1
(1.00)
0.347
(1.00)
0.404
(1.00)
0.616
(1.00)
DEL PEAK 12(9P21 3) MUTATION ANALYSIS 29 (56%) 23 0.55
(1.00)
0.879
(1.00)
0.214
(1.00)
0.644
(1.00)
0.329
(1.00)
0.173
(1.00)
0.785
(1.00)
0.788
(1.00)
0.233
(1.00)
0.521
(1.00)
0.00132
(0.634)
0.306
(1.00)
DEL PEAK 13(10Q23 2) MUTATION ANALYSIS 10 (19%) 42 0.253
(1.00)
0.206
(1.00)
0.738
(1.00)
1
(1.00)
1
(1.00)
0.137
(1.00)
0.483
(1.00)
1
(1.00)
0.152
(1.00)
0.422
(1.00)
0.348
(1.00)
DEL PEAK 14(11P15 4) MUTATION ANALYSIS 10 (19%) 42 0.119
(1.00)
0.876
(1.00)
0.789
(1.00)
0.569
(1.00)
0.42
(1.00)
0.0327
(1.00)
1
(1.00)
0.655
(1.00)
0.436
(1.00)
0.773
(1.00)
0.639
(1.00)
0.272
(1.00)
DEL PEAK 15(12P12 3) MUTATION ANALYSIS 8 (15%) 44 0.0294
(1.00)
0.71
(1.00)
0.709
(1.00)
1
(1.00)
1
(1.00)
0.373
(1.00)
0.123
(1.00)
0.538
(1.00)
0.0635
(1.00)
0.189
(1.00)
DEL PEAK 16(12Q12) MUTATION ANALYSIS 7 (13%) 45 0.0275
(1.00)
0.929
(1.00)
0.354
(1.00)
0.53
(1.00)
0.331
(1.00)
0.0134
(1.00)
1
(1.00)
1
(1.00)
0.599
(1.00)
0.755
(1.00)
0.198
(1.00)
DEL PEAK 17(12Q24 31) MUTATION ANALYSIS 12 (23%) 40 0.902
(1.00)
0.99
(1.00)
0.703
(1.00)
1
(1.00)
1
(1.00)
0.144
(1.00)
1
(1.00)
1
(1.00)
0.932
(1.00)
0.752
(1.00)
0.349
(1.00)
0.0714
(1.00)
DEL PEAK 18(15Q15 1) MUTATION ANALYSIS 9 (17%) 43 0.614
(1.00)
0.217
(1.00)
0.566
(1.00)
1
(1.00)
1
(1.00)
0.338
(1.00)
0.272
(1.00)
0.638
(1.00)
0.379
(1.00)
0.461
(1.00)
DEL PEAK 19(17P11 2) MUTATION ANALYSIS 19 (37%) 33 0.106
(1.00)
0.741
(1.00)
0.31
(1.00)
0.145
(1.00)
1
(1.00)
0.194
(1.00)
0.568
(1.00)
0.749
(1.00)
0.0459
(1.00)
0.208
(1.00)
0.00477
(1.00)
0.578
(1.00)
DEL PEAK 20(17Q22) MUTATION ANALYSIS 15 (29%) 37 0.404
(1.00)
0.596
(1.00)
0.16
(1.00)
0.305
(1.00)
0.47
(1.00)
0.0538
(1.00)
1
(1.00)
1
(1.00)
0.202
(1.00)
0.208
(1.00)
0.00415
(1.00)
0.873
(1.00)
DEL PEAK 21(18P11 32) MUTATION ANALYSIS 17 (33%) 35 0.622
(1.00)
0.00357
(1.00)
0.772
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
0.732
(1.00)
0.668
(1.00)
0.236
(1.00)
0.481
(1.00)
0.803
(1.00)
DEL PEAK 22(18Q12 1) MUTATION ANALYSIS 27 (52%) 25 0.456
(1.00)
0.863
(1.00)
0.544
(1.00)
0.662
(1.00)
1
(1.00)
0.886
(1.00)
0.788
(1.00)
0.61
(1.00)
0.622
(1.00)
0.0631
(1.00)
0.138
(1.00)
0.519
(1.00)
DEL PEAK 23(18Q21 2) MUTATION ANALYSIS 33 (63%) 19 0.669
(1.00)
0.301
(1.00)
0.261
(1.00)
0.342
(1.00)
0.317
(1.00)
0.295
(1.00)
0.775
(1.00)
0.551
(1.00)
0.917
(1.00)
0.00406
(1.00)
0.402
(1.00)
DEL PEAK 24(19Q13 33) MUTATION ANALYSIS 5 (10%) 47 0.399
(1.00)
0.769
(1.00)
0.844
(1.00)
1
(1.00)
0.578
(1.00)
1
(1.00)
0.652
(1.00)
1
(1.00)
0.242
(1.00)
0.529
(1.00)
DEL PEAK 25(21Q22 11) MUTATION ANALYSIS 16 (31%) 36 0.291
(1.00)
0.418
(1.00)
0.0625
(1.00)
0.308
(1.00)
0.0776
(1.00)
0.0377
(1.00)
0.229
(1.00)
0.514
(1.00)
0.609
(1.00)
0.81
(1.00)
0.189
(1.00)
0.0824
(1.00)
DEL PEAK 26(21Q22 11) MUTATION ANALYSIS 16 (31%) 36 0.291
(1.00)
0.418
(1.00)
0.0625
(1.00)
0.308
(1.00)
0.0776
(1.00)
0.0377
(1.00)
0.229
(1.00)
0.514
(1.00)
0.609
(1.00)
0.81
(1.00)
0.189
(1.00)
0.0824
(1.00)
DEL PEAK 27(22Q13 31) MUTATION ANALYSIS 12 (23%) 40 0.261
(1.00)
0.552
(1.00)
0.126
(1.00)
0.578
(1.00)
0.709
(1.00)
0.0102
(1.00)
0.186
(1.00)
0.658
(1.00)
0.00809
(1.00)
0.711
(1.00)
0.0185
(1.00)
0.234
(1.00)
DEL PEAK 28(XQ21 1) MUTATION ANALYSIS 6 (12%) 46 0.732
(1.00)
0.848
(1.00)
0.777
(1.00)
1
(1.00)
0.316
(1.00)
0.375
(1.00)
0.397
(1.00)
0.416
(1.00)
0.281
(1.00)
0.665
(1.00)
Methods & Data
Input
  • Copy number data file = transformed.cor.cli.txt

  • Clinical data file = PAAD-TP.clin.merged.picked.txt

  • Number of patients = 52

  • Number of significantly focal cnvs = 44

  • Number of selected clinical features = 12

  • Exclude genes that fewer than K tumors have mutations, K = 3

Survival analysis

For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R

Student's t-test analysis

For continuous numerical clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the clinical values between tumors with and without gene mutations using 't.test' function in R

Chi-square test

For multi-class clinical features (nominal or ordinal), Chi-square tests (Greenwood and Nikulin 1996) were used to estimate the P values using the 'chisq.test' function in R

Fisher's exact test

For binary or multi-class clinical features (nominal or ordinal), two-tailed Fisher's exact tests (Fisher 1922) were used to estimate the P values using the 'fisher.test' function in R

Q value calculation

For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.

Download Results

In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.

References
[1] Bland and Altman, Statistics notes: The logrank test, BMJ 328(7447):1073 (2004)
[2] Lehmann and Romano, Testing Statistical Hypotheses (3E ed.), New York: Springer. ISBN 0387988645 (2005)
[3] Greenwood and Nikulin, A guide to chi-squared testing, Wiley, New York. ISBN 047155779X (1996)
[4] Fisher, R.A., On the interpretation of chi-square from contingency tables, and the calculation of P, Journal of the Royal Statistical Society 85(1):87-94 (1922)
[5] Benjamini and Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, Journal of the Royal Statistical Society Series B 59:289-300 (1995)